Identification of cytochrome P450 isoforms involved in the metabolism of loperamide in human liver microsomes
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim K.-A. | - |
dc.contributor.author | Chung J. | - |
dc.contributor.author | Jung D.-H. | - |
dc.contributor.author | Park J.-Y. | - |
dc.date.available | 2020-11-03T17:51:53Z | - |
dc.date.issued | 2004 | - |
dc.identifier.issn | 0031-6970 | - |
dc.identifier.issn | 1432-1041 | - |
dc.identifier.uri | https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/20878 | - |
dc.description.abstract | Objective: The purpose of the present study was to elucidate the cytochrome P450 (P450) isoform(s) involved in the metabolism of loperamide (LOP) to N-demethylated LOP (DLOP) in human liver microsomes. Methods: Three established approaches were used to identify the P450 isoforms responsible for LOP N-demethylation using human liver microsomes and cDNA-expressed P450 isoforms: (1) correlation of LOP N-demethylation activity with marker P450 activities in a panel of human liver microsomes, (2) inhibition of enzyme activity by P450-selective inhibitors, and (3) measurement of DLOP formation by cDNA-expressed P450 isoforms. The relative contribution of P450 isoforms involved in LOP N-demethylation in human liver microsomes were estimated by applying relative activity factor (RAF) values. Results: The formation rate of DLOP showed biphasic kinetics, suggesting the involvement of multiple P450 isoforms. Apparent Km and Vmax values were 21.1 μM and 122.3 pmol/min per milligram of protein for the high-affinity component and 83.9 μM and 412.0 pmol/ min per milligram of protein for the low-affinity component, respectively. Of the cDNA-expressed P450 s tested, CYP2B6, CYP2C8, CYP2D6, and CYP3A4 catalyzed LOP N-demethylation. LOP N-demethylation was significantly inhibited when coincubated with quercetin (a CYP2C8 inhibitor) and ketoconazole (a CYP3A4 inhibitor) by 40 and 90%, respectively, but other chemical inhibitors tested showed weak or no significant inhibition. DLOP formation was highly correlated with CYP3A4-catalyzed midazolam 1-hydroxylation (rs = 0.829; P < 0.01), CYP2B6-catalzyed 7-ethoxy4- trifluoromethylcoumarin O-deethylation (rs = 0.691; P < 0.05), and CYP2C8-catalyzed paclitaxel 6α-hydroxylation (rs = 0.797; P < 0.05). Conclusion: CYP2B6, CYP2C8, CYP2D6, and CYP3A4 catalyze LOP N-demethylation in human liver microsomes, and among them, CYP2C8 and CYP3A4 may play a crucial role in LOP metabolism at the therapeutic concentrations of LOP. Coadministration of these P450 inhibitors may cause drug interactions with LOP. However, the clinical significance of potential interaction of LOP metabolism by CYP2C8 and CYP3A4 inhibitors should be studied further. © Springer-Verlag 2004. | - |
dc.format.extent | 7 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.title | Identification of cytochrome P450 isoforms involved in the metabolism of loperamide in human liver microsomes | - |
dc.type | Article | - |
dc.publisher.location | 독일 | - |
dc.identifier.doi | 10.1007/s00228-004-0815-3 | - |
dc.identifier.scopusid | 2-s2.0-8744278943 | - |
dc.identifier.bibliographicCitation | European Journal of Clinical Pharmacology, v.60, no.8, pp 575 - 581 | - |
dc.citation.title | European Journal of Clinical Pharmacology | - |
dc.citation.volume | 60 | - |
dc.citation.number | 8 | - |
dc.citation.startPage | 575 | - |
dc.citation.endPage | 581 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scopus | - |
dc.subject.keywordPlus | 7 ethoxy 4 trifluoromethylcoumarin | - |
dc.subject.keywordPlus | alpha hydroxymidazolam | - |
dc.subject.keywordPlus | complementary DNA | - |
dc.subject.keywordPlus | coumarin | - |
dc.subject.keywordPlus | coumarin derivative | - |
dc.subject.keywordPlus | cytochrome P450 | - |
dc.subject.keywordPlus | cytochrome P450 2B6 | - |
dc.subject.keywordPlus | cytochrome P450 2C8 | - |
dc.subject.keywordPlus | cytochrome P450 2D6 | - |
dc.subject.keywordPlus | cytochrome P450 3A4 | - |
dc.subject.keywordPlus | cytochrome P450 inhibitor | - |
dc.subject.keywordPlus | drug metabolite | - |
dc.subject.keywordPlus | furafylline | - |
dc.subject.keywordPlus | isoprotein | - |
dc.subject.keywordPlus | ketoconazole | - |
dc.subject.keywordPlus | loperamide | - |
dc.subject.keywordPlus | midazolam | - |
dc.subject.keywordPlus | norloperamide | - |
dc.subject.keywordPlus | omeprazole | - |
dc.subject.keywordPlus | orphenadrine | - |
dc.subject.keywordPlus | paclitaxel | - |
dc.subject.keywordPlus | quercetin | - |
dc.subject.keywordPlus | quinidine | - |
dc.subject.keywordPlus | sulfaphenazole | - |
dc.subject.keywordPlus | unclassified drug | - |
dc.subject.keywordPlus | zalcitabine | - |
dc.subject.keywordPlus | article | - |
dc.subject.keywordPlus | catalysis | - |
dc.subject.keywordPlus | correlation analysis | - |
dc.subject.keywordPlus | demethylation | - |
dc.subject.keywordPlus | drug metabolism | - |
dc.subject.keywordPlus | enzyme activity | - |
dc.subject.keywordPlus | enzyme inhibition | - |
dc.subject.keywordPlus | human | - |
dc.subject.keywordPlus | human cell | - |
dc.subject.keywordPlus | hydroxylation | - |
dc.subject.keywordPlus | liver microsome | - |
dc.subject.keywordPlus | priority journal | - |
dc.subject.keywordPlus | protein analysis | - |
dc.subject.keywordPlus | protein expression | - |
dc.subject.keywordPlus | protein function | - |
dc.subject.keywordPlus | Antidiarrheals | - |
dc.subject.keywordPlus | Cytochrome P-450 Enzyme System | - |
dc.subject.keywordPlus | Humans | - |
dc.subject.keywordPlus | Isoenzymes | - |
dc.subject.keywordPlus | Loperamide | - |
dc.subject.keywordPlus | Microsomes, Liver | - |
dc.subject.keywordAuthor | CYP2C8 | - |
dc.subject.keywordAuthor | CYP3A4 | - |
dc.subject.keywordAuthor | Cytochrome P450 (P450) | - |
dc.subject.keywordAuthor | Human liver microsomes | - |
dc.subject.keywordAuthor | Loperamide | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
73, Goryeodae-ro, Seongbuk-gu, Seoul, Republic of Korea (02841)82-2-2286-1265
COPYRIGHT 2020 KOREA UNIVERSITY MEDICAL LIBRARY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.